The law of survival for pharmaceutical companies in 2022: Innovative drug companies are big names, but they won’t go

Resource is the biggest industry barrier for pharmaceutical representatives. The 3 million pharmaceutical representatives who have been “laid off” hundreds of times by the industry media will be “sad year after year” in 2022?”At the end of the day, resources are the biggest barrier.”That’s how one longtime medical representative described the job at the end… Read more The law of survival for pharmaceutical companies in 2022: Innovative drug companies are big names, but they won’t go

Jinghua Pharmaceutical will increase its r&d investment by 20% in 2021 with less than half of its r&d staff

March 30, Essence pharmaceutical (002349.SZ) low open higher, as of the close, at 22.54 yuan/share, up 4.06%, stopped the short-term new high after three consecutive declines.As the main body of its API sector, Senxuan Pharmaceutical (830946.BJ), whose dioxane products are mainly used in the production of Remdesivir (COVID-19 treatment related drugs), “mother is precious” essence… Read more Jinghua Pharmaceutical will increase its r&d investment by 20% in 2021 with less than half of its r&d staff